Axoft raises $55 million after implanting its ultra-soft brain probes in more than 11 patients
The Series A, led by C.P. Group Innovation, funds global trials and manufacturing of its Fleuron-based implantable BCI.
Cambridge, Massachusetts-based Axoft has raised an oversubscribed $55 million Series A led by C.P. Group Innovation, bringing total funding to more than $60 million. Its probes are made of Fleuron, a material the company says is up to 10,000 times softer than standard polyimide, designed to move with brain tissue. Axoft has implanted them temporarily in more than 11 patients at sites including Mass General Brigham and a hospital in Shanghai. It plans to build a manufacturing cleanroom near Boston and file with the FDA next year.
Softer materials aim to solve one of the main problems with implants: scarring that degrades signals over time.
Learn more: Biocompatibility · Axoft